Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Grifols, S.A.NASDAQ: GRFS

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows in line with its trailing trend

Q2 FY2026 depreciation & amortization of €107M rose 0.0% year over year, behind the +1.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.

Context

  • Depreciation & amortization amounted to 6.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +1.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€107M+1.2% QoQ
Last fiscal yearDec 2025
€432.24M-1.3% YoY
LTMJun 2026
€443.93M+1.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-1.3%——
3-year CAGR+1.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
432.24M EUR
Year-over-year change
-1.3%
4-year CAGR
+4.7%

Depreciation & Amortization vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.5% is the highest of 9, against a peer median of -4.3%.
  • Depreciation & amortization amounts to 6.0% of revenue for GRFS, versus a peer median of 8.0%.
GRFS Competitors
Depreciation & Amortization for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$2.54B USD-19.0%-1.6%5.3%
BDXBecton, Dickinson and CompanyLTM Sep 2026$2.24B USD-4.2%-0.7%11.1%
QDELQuidelOrtho CorporationLTM Mar 2026$447.8M USD+0.5%+15.9%16.9%
GRFSGrifols, S.A.LTM Jun 2026€443.93M EUR+1.5%+1.7%6.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M USD-23.5%+6.4%4.9%
HAEHaemonetics CorporationLTM Jun 2026$110.07M USD-4.5%+6.2%8.1%
TECHBio-Techne CorporationLTM Sep 2026$96.75M USD-8.8%-3.2%7.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M USD-3.2%+16.6%27.3%
ADMAADMA Biologics, Inc.LTM Jun 2026$7.69M USD-2.8%+4.4%1.5%
Peer median (excluding GRFS) —-4.3%+5.3%8.0%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.